An arrangement between Roche (RHHBY) and Novartis (NVS) to channel demand to an expensive drug for treating a serious vision problem breached European Union competition rules, the E.U. Court of Justice ruled on Tuesday. And while this is not the final step in the litigation, the decision is likely to provide encouragement to European governments struggling to contain health care costs.

Here’s the back story: The ruling upheld a 2014 decision by Italy’s antitrust authority that the drug makers colluded to boost sales of Lucentis, a pricey treatment for age-related macular degeneration they jointly market, and discredited the cheaper Avastin drug by emphasizing potential side effects. The regulator fined each company about $110 million, which the drug makers subsequently appealed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy